Randomized, Open-label, Multi-center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-monthly Ibandronate and Once-weekly Risedronate. A Six-month, Two-sequence, and Two-period Crossover Study
Phase of Trial: Phase IV
Latest Information Update: 28 Aug 2015
At a glance
- Drugs Ibandronic acid (Primary) ; Risedronic acid
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 19 Sep 2008 Status changed from active, no longer recruiting to completed, as reported by Roche.
- 21 Nov 2006 New trial record.